Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy

1. Collaboration: Gilead Sciences and Cartography Biosciences have entered a multi-year strategic collaboration to discover and develop therapies for triple-negative breast cancer and lung adenocarcinoma.
2. Platforms: Cartography's ATLAS and SUMMIT platforms will be used to identify novel tumor-selective target antigens and pairs of antigens.
3. Financial Terms: Cartography will receive an upfront payment of $20 million, with potential for additional near-term and future milestones.
4. Target Identification: Gilead can opt in on multiple targets identified through this collaboration and will undertake all further research, development, and commercialization of programs against those targets.
5. Therapeutic Focus: The collaboration aims to develop targeted therapies for patients with triple-negative breast cancer and lung adenocarcinoma, leveraging Cartography's expertise in oncology and drug development.